Results 151 to 160 of about 51,890 (248)

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

open access: yesInterdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang   +10 more
wiley   +1 more source

Targeting eIF5A combats breast cancer progression by ClpP‐dependent mitochondrial oxidative stress

open access: yesInterdisciplinary Medicine, EarlyView.
This study identified the eIF5A‐ClpP axis as a key driver of breast cancer progression. Targeting eIF5A suppresses tumor growth by inducing ClpP‐dependent mitochondrial oxidative stress, revealing a novel therapeutic vulnerability. Abstract Breast cancer (BC) poses a persistent global health challenge, necessitating new therapeutic targets.
Jinmei Zhu   +13 more
wiley   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

open access: yesInterdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione   +2 more
wiley   +1 more source

Immunomodulation of the Prostate Tumor Microenvironment Following Inorganic Arsenic Exposure

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT The tumor microenvironment (TME) influences prostate cancer (PCa) progression through stromal and immune interactions. Adipose‐derived mesenchymal stromal cells (ASCs) modulate immune tone, while inorganic arsenic (iAs), a widespread toxicant, is linked to immune suppression and carcinogenesis.
Joseph J. Shearer   +4 more
wiley   +1 more source

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

open access: yesJournal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel   +2 more
wiley   +1 more source

IMPACT OF NAD+ SYNTHESIS ENZYMES ON MULTIPLE MYELOMA PATIENT OUTCOMES AND ONGOING INVESTIGATION OF MECHANISMS OF FAMILIAL CLUSTERING OF MULTIPLE MYELOMA IN NOVA SCOTIA

open access: yes
Multiple myeloma (MM) is an incurable plasma cell neoplasm, which makes it ideal for novel therapeutic targets such as Nicotinamide Dinucleotide (NAD+). NAD+ is synthesized through one of three pathways: catalyzed by NAMPT, NAPRT, or IDO. We compared the
Crone, Lara
core  

Molecular Functions and Drug Prediction of MMP1 and TGFBR2 in Nasopharyngeal Carcinoma

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
MMP1 and TGFBR2 were validated by machine learning and external datasets as the candidate genes. Dexamethasone showed strong binding affinity to MMP1 (−7.72 kcal/mol) and TGFBR2 (−7.27 kcal/mol) in docking studies. Knockdown of MMP1 repressed the malignant phenotypes of NPC cells.
Feng Wang   +5 more
wiley   +1 more source

Pseudohyperphosphatemia in Multiple Myeloma: A Systematic Review of Case Reports and Case Series

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Pseudohyperphosphatemia (PHP) is a clinically significant laboratory artifact in patients with multiple myeloma (MM). It is often caused by paraprotein interference with phosphate assays. This systematic review summarizes reported cases, underlying mechanisms, and diagnostic approaches to distinguish spurious from true hyperphosphatemia.
Mahsa Dabir   +3 more
wiley   +1 more source

Panobinostat for the treatment of multiple myeloma: the evidence to date

open access: yes, 2015
Hanna Bailey,1 David D Stenehjem,1,2 Sunil Sharma1 1Huntsman Cancer Institute, 2Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, UT, USA Abstract: Multiple myeloma is a malignancy involving ...
Sharma S, Bailey H, Stenehjem DD
core  

Home - About - Disclaimer - Privacy